Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy
Akanksha Behl1, Parul Sarwalia2, Sushil Kumar2
1Centre for Biotechnology, Maharshi Dayanand University, Rohtak, Haryana 124 001, India.
Molecular Pharmaceutics
|May 31, 2022
Summary
This study developed dual-loaded nanoparticles combining Gemcitabine (Gem) and MUC1 inhibitors for breast cancer therapy. This combination enhanced anticancer efficacy and reduced toxicity compared to individual treatments.
Area of Science:
- Nanotechnology
- Pharmacology
- Oncology
Background:
- Gemcitabine (Gem) is an effective antineoplastic agent for breast cancer, but its efficacy is limited by off-target effects.
- MUC1 inhibitors offer potential synergistic effects with chemotherapy.
- Polymeric nanoparticles (NPs) can improve drug delivery and reduce toxicity.
Purpose of the Study:
- To develop and evaluate dual-loaded polymeric nanoparticles (NPs) co-encapsulating Gemcitabine (Gem) and a MUC1 inhibitor.
- To assess the synergistic potential of this combination therapy in reducing toxicity and enhancing therapeutic efficacy.
- To investigate the underlying mechanisms of action, including apoptosis and autophagy induction.
Main Methods:
- Polymeric nanoparticles (PEG-PCL) co-loaded with Gemcitabine and a MUC1 inhibitor were prepared using the double emulsion solvent evaporation method.
- Characterization of NPs included size (128 nm), shape (spherical), and drug loading.
- In vitro studies involved cytotoxicity assays (IC50), mechanistic investigations (MMP loss, clonogenic assay, Annexin V FITC, Western blotting, AO staining) in MCF-7 cells.
- In vivo efficacy was evaluated in Ehrlich ascites tumor (EAT) bearing mice.
Main Results:
- The developed NPs were spherical with an average size of 128 nm.
- Co-loaded NPs demonstrated synergistic effects, significantly decreasing IC50 values.
- In vitro studies showed enhanced apoptosis, autophagy induction, loss of mitochondrial membrane potential (MMP), and reduced clonogenic potential.
- Western blotting confirmed increased caspase-3 and decreased Bcl-2 protein expression, indicative of apoptosis.
- In vivo studies in EAT mice showed superior efficacy of Gem-MUC1 inhibitor NPs compared to monotherapies.
Conclusions:
- Dual-loaded Gemcitabine and MUC1 inhibitor nanoparticles represent a promising strategy for enhanced breast cancer therapy.
- This combination approach effectively reduces dose-related toxicities and improves therapeutic outcomes.
- The synergistic action involves the induction of apoptosis and autophagy, highlighting a novel therapeutic mechanism.
